In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

Gene Therapy: Spark Charts A Course From Science To Payer And Patient Satisfaction

Gene therapy’s promise depends on the ecosystem now being built to deliver real product to patients – safely and at quantities that match the soaring expectations fed by the curative potential of the science. To assess the state of play, In Vivo talks to the man who leads the team responsible for bringing forward the first US-approved gene therapy to treat an incurable, inherited genetic condition: John Furey, chief operating officer of Spark Therapeutics

C-Suite Speaks Leadership Strategy
Advertisement

Latest From Market Access

US Drug Pricing Reforms Testing Limits Of Executive Action

Congressional inaction on drug pricing legislation has meant the Trump Administration is pursuing a menu of regulatory approaches. For the most part, that means slower and incremental change.

 

United States Pricing Strategies

Rebate Reform: Big Changes Are Looming For The US Drug Market

Changing US drug rebating policy is like throwing an activated grenade into the middle of the American drug distribution system. Yet, increasingly it seems the US drug market is poised for a big shake up when it comes to the way pharmaceuticals manufacturers price their drugs, negotiate market access with payers, and pay back-end discounts to offset the cost of their products. 

United States Market Access

The Oncology Burden Of Proof: Learning From The PD-1 Market

As more and more immuno-oncology products reach the market, the sustainability challenge persists: biopharmaceutical companies are seeking fair reimbursement deals that recognize their innovations, and struggling health care systems worldwide are pushing the burden of proof back onto the shoulders of drug developers.

Market Access ImmunoOncology

Brexit No Certain Thing For European Medtech Groups Desperate To Plan Futures

Medtech stakeholders were reminded at the UK's largest regulatory forum that, for business in general, and medical technology manufacturers in particular, those willing to make the best of Brexit are still having to work in the dark. The lack of useful government outreach is frustrating most efforts to secure business continuity. And that is without factoring in the huge regulatory changes that the EU's twin medical device regulations – the MDR and IVDR – will bring.

Brexit Market Access

The Advantages Of Providing Access To Unlicensed Medicines

Providing access to novel medicines through early access programs or supplying markets where medicines remain unlicensed has key benefits for the innovative drug development industry; revealing market insights and strategic opportunities.

Market Access Pricing Strategies

Spark Therapeutics: Calculating The Price Of A Cure

John Furey, chief operating officer of Spark Therapeutics, discusses how the company has created a value framework for the first US-approved gene therapy to treat an incurable, inherited genetic condition: Luxturna  (voretegene neparvovec-ryzl).  He also highlights the remaining access and reimbursement challenges for this novel gene therapy, which is approved specifically for treatment of inherited retinal blindness from a rare RPE65 gene mutation. 
Market Access Strategy
See All
UsernamePublicRestriction

Register